Table 2.
Clinicopathological feature | Cases |
CEA mRNA level (pre-) |
χ2 test |
CEA mRNA level (post-) |
χ2 test |
||||
Low | High | χ2 | P value | Low | High | χ2 | P value | ||
Gender | 1.891 | 0.169 | 1.327 | 0.249 | |||||
Male | 102 | 38 (37.3) | 64 (62.7) | 44 (43.1) | 58 (56.9) | ||||
Female | 27 | 14 (51.9) | 13 (48.1) | 15 (55.6) | 12 (44.4) | ||||
Age (yr) | 0.413 | 0.521 | 1.121 | 0.290 | |||||
≤ 60 | 59 | 22 (37.3) | 37 (62.7) | 24 (40.7) | 35 (59.3) | ||||
> 60 | 70 | 30 (42.9) | 40 (57.1) | 35 (50.0) | 35 (50.0) | ||||
Tumor size (cm) | 0.078 | 0.780 | 5.757 | 0.016 | |||||
≤ 4 | 75 | 31 (41.3) | 44 (58.7) | 41 (54.7) | 34 (45.3) | ||||
> 4 | 54 | 21 (38.9) | 33 (61.1) | 18 (33.3) | 36 (66.7) | ||||
Histological grade | 3.024 | 0.082 | 2.423 | 0.12 | |||||
Well/moderately differentiated | 99 | 44 (44.4) | 55 (55.6) | 49 (49.5) | 50 (50.5) | ||||
Poorly differentiated/undifferentiated | 30 | 8 (26.7) | 22 (73.3) | 10 (33.3) | 20 (66.7) | ||||
Depth of tumor invasion | 4.653 | 0.031 | 0.966 | 0.326 | |||||
T1-T2 | 34 | 19 (55.9) | 15 (44.1) | 18 (52.9) | 16 (47.1) | ||||
T3-T4 | 95 | 33 (34.7) | 62 (65.3) | 41 (43.2) | 54 (56.8) | ||||
Lymph node status | 9.871 | 0.002 | 7.012 | 0.008 | |||||
Negative | 78 | 40 (51.3) | 38 (48.7) | 43 (55.1) | 35 (44.9) | ||||
Positive | 51 | 12 (23.5) | 39 (76.5) | 16 (31.4) | 35 (68.6) | ||||
TNM stage | 6.063 | 0.048 | 7.379 | 0.025 | |||||
I | 11 | 6 (54.5) | 5 (45.5) | 9 (81.8) | 2 (18.2) | ||||
II | 75 | 35 (46.7) | 40 (53.3) | 34 (45.3) | 41 (54.7) | ||||
III | 43 | 11 (25.6) | 32 (74.4) | 16 (37.2) | 27 (62.8) |
CK19: Cytokeratin 19; CEA: Carcinoembryonic antigen; TNM: Tumor-node-metastasis.